A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
about
Molecular and therapeutic potential and toxicity of valproic acidHistone deacetylase inhibitors induce growth arrest and differentiation in uveal melanomaEpigenetic treatment of solid tumours: a review of clinical trialsImproved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesEffects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell lineHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group reportInterpreting clinical assays for histone deacetylase inhibitors.Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment scheduleCotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Epigenetics of melanoma: implications for immune-based therapies.Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid.Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.Effects of histone deacetylase inhibitors on rat mesangial cells.Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.Effect of valproic acid on the outcome of glioblastoma multiforme.A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation.Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
P2860
Q21296867-9A903B1A-B4D5-4B4E-8117-7BF7FB73853DQ24606279-B8084B33-5356-4505-AEC4-2A4C3AC4583FQ26773803-3C67E60C-8B2E-438D-8D94-F4FBD60F4910Q33410559-5D3A3ABE-C88B-4A60-BB75-47B1FE4DFDC4Q33980682-EE1E1C82-85F2-480C-96D9-A92F753416C2Q34366588-E6801475-A002-455F-812B-2A3BC1CF7304Q34488424-A9F17442-2643-4DE5-BAB0-D060187CA4B1Q34722045-A809713F-69D3-4396-BE26-69E504B2C7B9Q35003657-D6665091-AC4A-4BBC-AECD-0A5BA4EE7437Q35577880-DDE87A20-CC04-4669-8E05-72E1331C6679Q35691532-20641B65-8867-4588-83A6-40D453DACD81Q36984572-90C53A0B-0CE7-474A-9593-A1C899CD7B79Q36985083-1AB97364-4F98-49AC-9616-34406BD371DFQ37959304-F48C1033-712F-406E-8BAA-700C73573E87Q38148588-18F6AC89-FE0A-4B9F-8022-59DA73658DB6Q38993736-3EC15CCD-B98B-4F5F-AA77-40B18A43D29CQ39273391-88175BF9-448C-4048-B996-1455D7DF9722Q39430288-1E86EEB2-FE50-4753-B5F9-6CDA407AB147Q43239274-1CF13D3D-E4B2-48A0-B4F1-2DA34354831FQ43285192-E39CF600-15EE-45B9-9FAB-DC8882C96823Q45231801-67A9AB78-9B78-4665-8582-E3FC518D788AQ47160397-1A149ACE-3058-48E4-8872-3AEFAAC19716Q48303460-586F3946-C79C-45E7-A791-EE4DFE94EF10Q50471854-77C0F168-9224-4BD6-A617-ED60366C1206Q58588998-84C1C702-490C-42DF-904D-0E487AFF2560
P2860
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
A phase I-II study of the hist ...... atients with advanced melanoma
@ast
A phase I-II study of the hist ...... atients with advanced melanoma
@en
A phase I-II study of the hist ...... atients with advanced melanoma
@nl
type
label
A phase I-II study of the hist ...... atients with advanced melanoma
@ast
A phase I-II study of the hist ...... atients with advanced melanoma
@en
A phase I-II study of the hist ...... atients with advanced melanoma
@nl
prefLabel
A phase I-II study of the hist ...... atients with advanced melanoma
@ast
A phase I-II study of the hist ...... atients with advanced melanoma
@en
A phase I-II study of the hist ...... atients with advanced melanoma
@nl
P2093
P2860
P356
P1476
A phase I-II study of the hist ...... atients with advanced melanoma
@en
P2093
A Goldhirsch
A Salmaggi
F Contegno
M Ballarini
P2860
P2888
P356
10.1038/SJ.BJC.6604817
P407
P577
2009-01-13T00:00:00Z
P5875
P6179
1012460142